Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma

Inclusion Criteria

• •1. Age ≥18 years old;
• •2. According to the WHO 2016 classification criteria, the CD20 positive diffuse large B-cell lymphoma (DLBCL) diagnosed by pathology should include the indicators of immunohistochemistry: CD10, BCL-2, MUM-1, BCL-6 and C-MYC;
• •3. Relapsed or refractory DLBCL.Patients younger than 65 years should relapse or progress after receiving at least second-line treatment, and patients 65 years of age and older could be intolerant to second-line treatment, and they who relapse or progress after receiving first-line treatment;
• •4. There is at least one measurable lesion, defined as measurable dual-diameter, intra-lymph node lesion, short diameter\> 1.5cm, extra-lymph node lesion short diameter\> 1.0cm;
• •5. Recurrence confirmed by pathological biopsy and CD20 positive;
• •6. ECOG score 0-2 points;
• •7. No autoimmune diseases;
• •8. Blood routine examination meets the following criteria:
• •1. Neutrophil count ≥ 1.5 x 109 / L,;
• •2. Platelet ≥ 75 x 109 / L,;
• •3. Hemoglobin ≥ 10.0 g / dL;
• •9. The main organ function meets the following criteria:
• •1. Aspartate aminotransferase and alanine aminotransferase ≤ 2.0 times the upper limit of normal value;
• •2. Bilirubin ≤ 2.0 mg / dL;
• •3. Creatinine clearance rate ≥ 60 mL / min;
• •10. Patients must agree to take effective contraceptive measures during the study according to the investigator's request;
• •11. Understand and voluntarily sign written informed consent.